Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa). Dorigo, O., MacDonald, L., Schindler, J., Bramhecha, Y., Torrey, H., Kaliaperumal, V., Hrytsenko, O., Dirk, B., Patterson, K., Stanford, M., Fiset, S. AMER SOC CLINICAL ONCOLOGY. 2020
View details for Web of Science ID 000560368302499